CHA Biotech wins government backing to advance cell and gene therapy platform
CHA Biotech has secured government backing for a three-and-a-half-year research project aimed at pushing its cell and gene therapy platforms toward clinical development, with 31.5 billion won ($22.7 million) in funding. The biotechnology company said Tuesday that it was selected for a follow-up research and development project under the 2026 K-HERO Development and Support Program, led by the…
CHA Biotech has secured government backing for a three-and-a-half-year research project aimed at advancing its cell and gene therapy platforms toward clinical development. The biotechnology company was selected for a follow-up research and development project under the 2026 K-HERO Development and Support Program, which is led by the Ministry of Science and ICT and administered by the Korea Industrial Technology Association.
The funding of 31.5 billion won ($22.7 million) will be used to develop and commercialize two platforms, CHAMS, a standardized source-cell platform based on mesenchymal stem cells, and CHAGE, which uses therapeutic genes to enhance cell function. CHA Biotech plans to combine these platforms into a development system that can be applied across a range of hard-to-treat diseases.
Brief written by urgent.news from The Korea Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
